|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01681 CONSUN PHARMA
Nominal 
13.930 -0.050 (-0.358%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 1,568,588 | 23.652% | 2,967,235 | 2,590,115 | 2,339,650 | 2,044,660 |
| Cost of Sales | (359,907) | 12.111% | (725,133) | (668,437) | (576,738) | (517,324) |
| Gross Profit | 1,208,681 | 27.562% | 2,242,102 | 1,921,678 | 1,762,912 | 1,527,336 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (763) | -- | (66) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 535,238 | 23.339% | 1,020,106 | 863,703 | 746,393 | 695,861 | |
| Taxation | (32,389) | -1.846% | (102,732) | (77,149) | (62,696) | (108,744) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (4,550) | 280.753% | (6,916) | (2,020) | (790) | 3,055 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 498,299 | 24.648% | 910,458 | 784,534 | 682,907 | 590,172 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (40,599) | 34.742% | (63,413) | (47,653) | (41,481) | (26,343) |
| Depreciation & Amortisation | 30,924 | -17.375% | 63,993 | 78,089 | 76,355 | 72,989 |
| Directors' Emoluments | -- | -- | 23,890 | 41,942 | 39,301 | 37,542 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 59.000 | 18.000% | 111.000 | 99.000 | 86.000 | 74.000 |
| DPS (cts) | 30.112 | -- | 55.372 | 68.015 | 26.265 | 24.361 |
| Dividend Payout Ratio (%) | 51.036% | -- | 49.884% | 68.702% | 30.541% | 32.920% |
| Cash flow per share ($) | -- | -- | 1.324 | 1.035 | 1.199 | 0.905 |
| NBV per share ($) | 5.104 | -- | 4.824 | 4.472 | 3.897 | 3.176 |
| Remarks: | Real time quote last updated: 21/08/2025 09:43 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 498,299 |
| %Change | 24.648% |
| EPS / (LPS) | RMB 0.590 |
| NBV Per Share (¥) | RMB 5.104 |